15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $510M | $147M | 57.4% | 37.5% | $28M | $72M | $88M |
| 2024 | $426M | $198M | 51.5% | 32.6% | $110M | $72M | $103M |
| 2023 | $258M | -$28M | 34.4% | 8.4% | $4M | — | $51M |
| 2022 | $154M | -$66M | 22.9% | -25.5% | -$73M | — | $87M |
| 2021 | $81M | -$72M | 1.4% | -72.1% | -$126M | — | $51M |
| 2020 | $42M | -$76M | -45.2% | -153.8% | -$115M | — | $56M |
| 2020 | — | $321M | — | — | — | — | $60M |
| 2020 | — | $304M | — | — | — | — | $76M |
| 2019 | — | -$48M | — | — | -$80M | $0 | $27M |
| 2018 | — | -$66M | — | — | -$65M | $3M | $27M |
| 2017 | — | -$44M | — | — | -$40M | $3M | $43M |
| 2016 | — | -$20M | — | — | -$18M | $2M | $10M |
| 2015 | — | -$18M | — | — | -$15M | — | $10M |
| 2014 | — | -$17M | — | — | -$17M | — | $17M |
| 2013 | — | -$16M | — | — | -$11M | — | $26M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $114M | $45M | 70.5% | 50.9% | $56M | $197M | $138M |
| Dec '25 | $139M | $49M | 63.8% | 45.1% | $35M | $72M | $88M |
| Sep '25 | $134M | $36M | 56.3% | 38.0% | -$1M | $72M | $61M |
| Jun '25 | $122M | $34M | 55.1% | 35.1% | $19M | — | $90M |
| Mar '25 | $115M | $27M | 53.2% | 30.4% | -$24M | — | $72M |
| Dec '24 | $118M | $112M | 53.9% | 32.6% | $47M | $72M | $103M |
| Sep '24 | $120M | $36M | 49.8% | 33.1% | $24M | — | $87M |
| Jun '24 | $107M | $32M | 53.6% | 36.6% | $44M | — | $88M |
| Mar '24 | $82M | $18M | 47.8% | 26.7% | -$5M | — | $45M |
| Dec '23 | $74M | -$18M | 42.1% | 19.3% | $16M | — | $51M |
| Sep '23 | $67M | $3M | 36.6% | 12.9% | $11M | — | $74M |
| Jun '23 | $60M | -$6M | 27.8% | -0.8% | -$7M | — | $63M |
| Mar '23 | $57M | -$7M | 29.0% | -1.4% | -$17M | — | $69M |
| Dec '22 | $50M | -$12M | 28.4% | -12.1% | -$11M | — | $87M |
| Sep '22 | $41M | -$15M | 23.5% | -22.7% | -$17M | — | $35M |
| Jun '22 | $34M | -$14M | 22.9% | -27.1% | -$17M | — | $52M |
| Mar '22 | $29M | -$25M | 12.6% | -50.9% | -$29M | — | $70M |
| Dec '21 | $26M | -$17M | 13.3% | -50.0% | -$37M | — | $51M |
| Sep '21 | $21M | -$18M | 1.9% | -69.8% | -$16M | — | $34M |
| Jun '21 | $18M | -$19M | -5.6% | -87.4% | -$37M | — | $42M |
How the market has priced ADMA against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Adma Biologics, Inc.'s revenue has grown 64.6% per year, and net income declined 13.5% per year. These are computed facts, not advice.
As of FY2025, Adma Biologics, Inc. reported $72M of total debt against $88M of cash; operating income covered interest expense 27×.
In FY2025, gross margin was 57.4%, operating margin 37.5%, and net margin 28.8%.
As of Jun '26, Adma Biologics, Inc. traded at a price-to-earnings ratio of about 13.8× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.